Sanofi treatment of phenylketonuria granted FDA orphan status

The FDA granted orphan status to Sanofi US Services’ adeno-associated virus-based vector with an engineered capsid serotype SNY001 harboring human phenylalanine hydroxylase cDNA as a treatment of phenylketonuria.